pct/09885247

Welcome to STN International! Enter x:x

LOGINID:sssptaul25txc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Jan 25  BLAST(R) searching in REGISTRY available in STN on the Web
 NEWS  3  Jan 29  FSTA has been reloaded and moves to weekly updates
 NEWS  4  Feb 01  DKILIT now produced by FIZ Karlsruhe and has a new update
                  frequency
 NEWS  5  Feb 19  Access via Tymnet and SprintNet Eliminated Effective 3/31/02
 NEWS  6  Mar 08  Gene Names now available in BIOSIS
 NEWS  7  Mar 22  TOXLIT no longer available
 NEWS  8  Mar 22  TRCTHERMO no longer available
 NEWS  9  Mar 28  US Provisional Priorities searched with P in CA/CAplus
                  and USPATFULL
 NEWS 10  Mar 28  LIPINSKI/CALC added for property searching in REGISTRY
 NEWS 11  Apr 02  PAPERCHEM no longer available on STN.  Use PAPERCHEM2 instead.
 NEWS 12  Apr 08  "Ask CAS" for self-help around the clock
 NEWS 13  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 14  Apr 09  ZDB will be removed from STN
 NEWS 15  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 16  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 17  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS 18  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS 19  Jun 03  New e-mail delivery for search results now available
 NEWS 20  Jun 10  MEDLINE Reload
 NEWS 21  Jun 10  PCTFULL has been reloaded

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:21:25 ON 27 JUN 2002

```
=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'ADISALERTS' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'BIOSIS' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 14:21:53 ON 27 JUN 2002

FILE 'CAPLUS' ENTERED AT 14:21:53 ON 27 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

FILE 'EMBASE' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.
```

pct/09885247

FILE 'ESBIOBASE' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (c) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:21:53 ON 27 JUN 2002

FILE 'NAPRALERT' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'PASCAL' ENTERED AT 14:21:53 ON 27 JUN 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PHIC' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 14:21:53 ON 27 JUN 2002
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 14:21:53 ON 27 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:21:53 ON 27 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s tamoxifene and atherosclerosis
L1 28 TAMOXIFENE AND ATHEROSCLEROSIS

=> d l1 1-28

pct/09885247

L1 ANSWER 1 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 2001-0215113 PASCAL
CP Copyright .COPYRGT. 2001 INIST-CNRS. All rights reserved.
TIEN Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced **atherosclerosis**
AU CLARKE Sarah C.; SCHOFIELD Peter M.; GRACE Andrew A.; METCALFE James C.; KIRSCHENLOHR Heide L.
CS Department of Cardiology, Papworth Hospital NHS Trust, Papworth Everard, United Kingdom; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
SO Circulation : (New York, N.Y.), (2001), 103(11), 1497-1502, 25 refs.
ISSN: 0009-7322 CODEN: CIRCAZ
DT Journal
BL Analytic
CY United States
LA English
AV INIST-5907, 354000098735150030

L1 ANSWER 2 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1999-0076891 PASCAL
CP Copyright .COPYRGT. 1999 INIST-CNRS. All rights reserved.
TIEN Effect of estrogens and antiestrogens on human breast cancer cells MCF-7 and on bovin aortic endothelial cells BAEC
TIFR Etude de l'effet des (anti)oestrogenes sur une lignee tumorale mammaire humaine MCF-7 et sur une culture primaire endotheliale aortique bovine ABAE
AU DELARUE Frederic; FAYE Jean-Charles (dir.)
CS Universite de Toulouse 3, Toulouse, France (tutelle)
SO (1998-07), 650 refs.
35 p.
Dissertation Information: Universite de Toulouse 3. Toulouse. FRA, Th. doct., 98TOU30110
DT Dissertation
BL Monographic
CY France
LA French
SL French; English
AV INIST-T 121738, T98TOU30110 0000; RBCCN-315552104, T98TOU30110 0000

L1 ANSWER 3 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1997-0521979 PASCAL
CP Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
TIEN Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice
AU ZYSOW B. R.; KAUSER K.; LAWN R. M.; RUBANYI G. M.
CS Falk Cardiovascular Research Center, Stanford University School of Medicine, Palo Alto, Calif, United States; Cardiovascular Department, Berlex Biosciences, Richmond, Calif, United States
SO Arteriosclerosis, thrombosis, and vascular biology, (1997), 17(9), 1741-1745, 37 refs.
ISSN: 1079-5642
DT Journal
BL Analytic
CY United States
LA English
AV INIST-19104, 354000068521240190

L1 ANSWER 4 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1997-0500608 PASCAL

pct/09885247

CP Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
TIEN Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates
AU WILLIAMS J. K.; HONORE E. K.; ADAMS M. R.
CS Comparative Medicine Clinical Research Center and the Department of Comparative Medicine, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC, United States
SO Circulation : (New York), (1997), 96(6), 1970-1975, 46 refs.
ISSN: 0009-7322 CODEN: CIRCAZ
DT Journal
BL Analytic
CY United States
LA English
AV INIST-5907, 354000069976220430

L1 ANSWER 5 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1997-0238609 PASCAL
CP Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
TIEN Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice
AU RECKLESS J.; METCALFE J. C.; GRAINGER D. J.
CS Department of Biochemistry, University of Cambridge, United Kingdom
SO Circulation : (New York), (1997), 95(6), 1542-1548, 36 refs.
ISSN: 0009-7322 CODEN: CIRCAZ
DT Journal
BL Analytic
CY United States
LA English
AV INIST-5907, 354000064450930300

L1 ANSWER 6 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1997-0205578 PASCAL
CP Copyright .COPYRGT. 1997 INIST-CNRS. All rights reserved.
TIEN Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery **atherosclerosis** in monkeys
AU WILLIAMS J. K.; WAGNER J. D.; LI Z.; GOLDEN D. L.; ADAMS M. R.
CS Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC, United States
SO Arteriosclerosis, thrombosis, and vascular biology, (1997), 17(2), 403-408, 49 refs.
ISSN: 1079-5642
DT Journal
BL Analytic
CY United States
LA English
AV INIST-19104, 354000063477450230

L1 ANSWER 7 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1996-0270945 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques
AU CLINE J. M.; PASCHOLD J. C.; ANTHONY M. S.; OBASANJO I. O.; ADAMS M. R.
CS Department of Comparative Medicine, Bowman Gray School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1040, United States
SO Fertility and sterility, (1996), 65(5), 1031-1035, 25 refs.
ISSN: 0015-0282 CODEN: FESTAS
DT Journal

BL Analytic
CY United States
LA English
AV INIST-4120, 354000043009770260

L1 ANSWER 8 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1996-0137800 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN Antiatherogenic effects of adjuvant antiestrogens : a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
AU SAARTO T.; BLOMQVIST C.; EHNHOLM C.; TASKINEN M.-R.; ELOMAA I.
CS Helsinki univ. cent. hosp., dep. oncology and internal medicine, 00290 Helsinki, Finland
SO Journal of clinical oncology, (1996), 14(2), 429-433, 34 refs.
ISSN: 0732-183X
DT Journal
BL Analytic
CY United States
LA English
AV INIST-20094, 354000052763170160

L1 ANSWER 9 OF 28 PASCAL COPYRIGHT 2002 INIST-CNRS. ALL RIGHTS RESERVED.
AN 1996-0017102 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN The effects of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
AU GREY A. B.; STAPLETON J. P.; EVANS M. C.; REID I. R.
CS Univ. Auckland, dep. medicine, Auckland, New Zealand
SO The Journal of clinical endocrinology and metabolism, (1995), 80(11), 3191-3195, 45 refs.
ISSN: 0021-972X CODEN: JCEMAZ
DT Journal
BL Analytic
CY United States
LA English
AV INIST-6022, 354000058936240180

L1 ANSWER 10 OF 28 USPATFULL
AN 2002:152632 USPATFULL
TI .alpha.v integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6410526 B1 20020625
AI US 2000-583522 20000531 (9)
PRAI US 1999-137101P 19990602 (60)
US 2000-179216P 20000131 (60)
DT Utility
FS GRANTED
LN.CNT 3656
INCL INCLM: 514/212.020
INCLS: 514/212.060; 514/215.000; 540/521.000; 540/543.000; 540/577.000; 540/580.000
NCL NCLM: 514/212.020
NCLS: 514/212.060; 514/215.000; 540/521.000; 540/543.000; 540/577.000; 540/580.000
IC [7]

ICM: A61K031-55
ICS: C07D487-02; A61P019-10
EXF 514/212.02; 514/212.06; 514/215; 540/521; 540/543; 540/577; 540/580

L1 ANSWER 11 OF 28 USPATFULL
AN 2002:92700 USPATFULL
TI Alpha v integrin receptor antagonists
IN Arison, Byron H., Watchung, NJ, UNITED STATES
Cui, Donghui, Newton, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Subramanian, Raju, Perkasie, PA, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES
PI US 2002049224 A1 20020425
AI US 2001-952084 A1 20010914 (9)
PRAI US 2000-232344P 20000914 (60)
DT Utility
FS APPLICATION
LN.CNT 1088
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A61K031-4745
ICS: C07D471-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 12 OF 28 USPATFULL
AN 2002:72890 USPATFULL
TI Alpha V integrin receptor antagonists
IN Coleman, Paul J., Wallingford, PA, UNITED STATES
Cui, Donghui, Newtown, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Landsdale, PA, UNITED STATES
Silva Elipe, Maria Victoria, Mountainside, NJ, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES
PI US 2002040030 A1 20020404
AI US 2001-953606 A1 20010914 (9)
PRAI US 2000-232262P 20000914 (60)
DT Utility
FS APPLICATION
LN.CNT 1296
INCL INCLM: 514/256.000
INCLS: 544/333.000
NCL NCLM: 514/256.000
NCLS: 544/333.000
IC [7]
ICM: C07D043-14
ICS: A61K031-506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 28 USPATFULL
AN 2002:67236 USPATFULL
TI Alpha V integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES

Hutchinson, John H., Philadelphia, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Perkins, James J., Churchville, PA, UNITED STATES
Steele, Thomas G., Schwenksville, PA, UNITED STATES
Wang, Jiabing, Chalfont, PA, UNITED STATES
Patane, Michael A., Billerica, MA, UNITED STATES
PI US 2002037889 A1 20020328
AI US 2001-766148 A1 20010119 (9)
PRAI US 2000-177168P 20000120 (60)
DT Utility
FS APPLICATION
LN.CNT 2835
INCL INCLM: 514/214.010
INCLS: 514/256.000; 514/278.000; 514/300.000; 514/340.000
NCL NCLM: 514/214.010
NCLS: 514/256.000; 514/278.000; 514/300.000; 514/340.000
IC [7]
ICM: A61K031-55
ICS: A61K031-505; A61K031-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 14 OF 28 USPATFULL
AN 2002:57802 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
Ihle, Nathan, Mercer Island, WA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6358970 B1 20020319
AI US 2000-599088 20000621 (9)
PRAI US 1999-140535P 19990623 (60)
DT Utility
FS GRANTED
LN.CNT 2558
INCL INCLM: 514/300.000
INCLS: 514/253.000; 540/597.000; 544/362.000; 546/122.000
NCL NCLM: 514/300.000
NCLS: 514/253.040; 540/597.000; 544/362.000; 546/122.000
IC [7]
ICM: A61K031-435
ICS: C07D471-04
EXF 546/122; 544/362; 514/300; 514/253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 15 OF 28 USPATFULL
AN 2002:17296 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES

PI US 2002010176 A1 20020124
AI US 2001-916977 A1 20010728 (9)
RLI Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING
Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS APPLICATION
LN.CNT 5336
INCL INCLM: 514/224.200
INCLS: 514/227.500; 514/238.200; 514/249.000; 514/252.120; 514/256.000; 514/258.000; 514/277.000; 514/412.000; 514/359.000; 514/550.000; 514/551.000; 560/149.000; 560/168.000; 548/570.000; 548/452.000; 546/341.000; 546/329.000; 544/399.000; 544/349.000
NCL NCLM: 514/224.200
NCLS: 514/227.500; 514/238.200; 514/249.000; 514/252.120; 514/256.000; 514/258.000; 514/277.000; 514/412.000; 514/359.000; 514/550.000; 514/551.000; 560/149.000; 560/168.000; 548/570.000; 548/452.000; 546/341.000; 546/329.000; 544/399.000; 544/349.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-495; C07D211-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 16 OF 28 USPATFULL
AN 2001:237948 USPATFULL
TI METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES
IN CHWALISZ, KRISTOF, BERLIN, Germany, Federal Republic of
GARFIELD, ROBERT E., FRIENDSWOOD, TX, United States
SHI, SHAO-QUING, GALVESTON, TX, United States
PI US 2001056068 A1 20011227
AI US 1998-34351 A1 19980304 (9)
DT Utility
FS APPLICATION
LN.CNT 1391
INCL INCLM: 514/021.000
NCL NCLM: 514/021.000
IC [7]
ICM: A61K038-00
ICS: A61K031-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 17 OF 28 USPATFULL
AN 2001:233621 USPATFULL
TI Alpha V integrin receptor antagonists
IN Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States
PI US 2001053853 A1 20011220
AI US 2001-767471 A1 20010123 (9)
PRAI US 2000-177792P 20000124 (60)

US 2000-230469P 20000906 (60)
DT Utility
FS APPLICATION
LN.CNT 4132
INCL INCLM: 544/295.000
INCLS: 544/296.000; 544/333.000
NCL NCLM: 544/295.000
NCLS: 544/296.000; 544/333.000
IC [7]
ICM: C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 28 USPATFULL
AN 2001:168133 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6297249 B1 20011002
AI US 1999-453847 19991202 (9)
RLI Division of Ser. No. US 1998-212082, filed on 15 Dec 1998
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS GRANTED
LN.CNT 4784
INCL INCLM: 514/256.000
INCLS: 514/302.000; 514/352.000; 544/333.000; 546/115.000; 546/312.000
NCL NCLM: 514/256.000
NCLS: 514/302.000; 514/352.000; 544/333.000; 546/115.000; 546/312.000
IC [7]
ICM: C07D401-06
ICS: C07D213-55; A61K031-444
EXF 544/333; 546/115; 546/312; 514/256; 514/302; 514/352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 19 OF 28 USPATFULL
AN 2001:121485 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6268378 B1 20010731
AI US 2000-498895 20000207 (9)
RLI Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS GRANTED
LN.CNT 4460
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000

IC [7]
ICM: A61K031-4375
ICS: C07D471-04
EXF 546/122; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 20 OF 28 USPATFULL
AN 2001:71543 USPATFULL
TI Bezazepine derivatives as .alpha.v integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6232308 B1 20010515
AI US 2000-496525 20000202 (9)
PRAI US 1999-118428P 19990203 (60)
DT Utility
FS Granted
LN.CNT 1967
INCL INCLM: 514/221.000
INCLS: 540/504.000; 540/509.000; 540/510.000; 540/511.000; 540/491.000; 540/523.000; 514/211.050; 514/212.070
NCL NCLM: 514/221.000
NCLS: 514/211.050; 514/212.070; 540/491.000; 540/504.000; 540/509.000; 540/510.000; 540/511.000; 540/523.000
IC [7]
ICM: A61K031-5513
ICS: C07D243-14; C07D471-04; C07D471-14
EXF 540/504; 540/509; 540/510; 540/511; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 21 OF 28 USPATFULL
AN 2001:48064 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6211191 B1 20010403
AI US 1998-212510 19981215 (9)
PRAI US 1997-69909P 19971217 (60)
US 1998-83250P 19980427 (60)
US 1998-92630P 19980713 (60)
DT Utility
FS Granted
LN.CNT 3544
INCL INCLM: 514/274.000
INCLS: 544/296.000; 544/316.000; 562/013.000
NCL NCLM: 514/274.000
NCLS: 544/296.000; 544/316.000; 562/013.000
IC [7]
ICM: C07D403-06
ICS: C07D401-06; A61K031-506; A61P019-02; A61P035-00
EXF 562/13; 544/296; 544/316; 514/274
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 22 OF 28 USPATFULL
AN 2000:92099 USPATFULL
TI Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
IN Hutchinson, John H., Philadelphia, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6090944 20000718

AI US 1999-371444 19990810 (9)
PRAI US 1998-96378P 19980813 (60)
DT Utility
FS Granted
LN.CNT 3589
INCL INCLM: 546/122.000
INCLS: 514/218.000; 514/252.000; 514/299.000; 514/300.000; 514/340.000; 514/390.000; 514/392.000; 540/492.000; 544/284.000; 546/122.000; 546/134.000; 546/274.000; 546/004.000; 546/300.000; 546/277.700; 548/304.700; 548/323.500; 548/324.500; 548/325.100
NCL NCLM: 546/122.000
NCLS: 540/492.000; 544/284.000; 546/004.000; 546/134.000; 546/274.400; 546/276.100; 546/277.700; 546/300.000; 548/304.700; 548/323.500; 548/324.500; 548/325.100
IC [7]
ICM: C07D471-02
ICS: C07D453-02; C07D401-06; A61K031-4375; A61N019-08; A61N019-10
EXF 546/122; 546/274.4; 546/277.7; 544/284; 540/492; 548/304.7; 514/300; 514/218; 514/392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 23 OF 28 USPATFULL
AN 2000:64874 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6066648 20000523
AI US 1998-212123 19981215 (9)
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS Granted
LN.CNT 4780
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A01N043-40
ICS: C07D471-04
EXF 546/122; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 24 OF 28 USPATFULL
AN 2000:44101 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6048861 20000411
AI US 1998-212082 19981215 (9)
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS Granted
LN.CNT 5443
INCL INCLM: 514/256.000
INCLS: 514/300.000; 544/333.000; 546/122.000; 546/123.000
NCL NCLM: 514/256.000
NCLS: 514/300.000; 544/333.000; 546/122.000; 546/123.000
IC [7]
ICM: C07D471-04
ICS: C07D401-06; C07D401-12; A61K031-44; A61K031-435
EXF 544/333; 546/122; 546/123; 514/256; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 25 OF 28 USPATFULL
AN 2000:34557 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6040311 20000321
AI US 1999-362528 19990728 (9)
PRAI US 1998-94478P 19980729 (60)
DT Utility
FS Granted
LN.CNT 2801
INCL INCLM: 514/275.000
INCLS: 514/300.000; 514/395.000; 514/398.000; 544/332.000; 546/122.000; 548/308.700; 548/321.500
NCL NCLM: 514/275.000
NCLS: 514/300.000; 514/395.000; 514/398.000; 544/332.000; 546/122.000; 548/308.700; 548/321.500
IC [7]
ICM: A61K031-505
ICS: A61K031-435; C07D239-42; C07D471-04
EXF 544/332; 546/122; 548/308.7; 548/321.5; 514/275; 514/300; 514/395; 514/398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 26 OF 28 USPATFULL
AN 2000:9915 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017926 20000125
AI US 1998-212079 19981215 (9)
PRAI US 1997-69910P 19971217 (60)

US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
US 1998-79197P 19980324 (60)
US 1998-79944P 19980330 (60)
US 1998-80397P 19980402 (60)
US 1998-92624P 19980713 (60)
US 1998-99948P 19980911 (60)
DT Utility
FS Granted
LN.CNT 5668
INCL INCLM: 514/300.000
INCLS: 514/230.500; 514/300.000; 514/333.000; 544/105.000; 544/335.000; 546/081.000; 546/082.000; 546/122.000; 546/256.000; 546/115.000; 546/118.000; 548/306.100
NCL NCLM: 514/300.000
NCLS: 514/230.500; 514/333.000; 544/105.000; 544/335.000; 546/081.000; 546/082.000; 546/115.000; 546/118.000; 546/122.000; 546/256.000; 548/306.100
IC [6]
ICM: A61K031-435
ICS: C07D471-04
EXF 546/122; 546/256; 546/81; 546/82; 544/105; 544/335; 548/306.1; 514/230.5; 514/333; 514/303; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 27 OF 28 USPATFULL
AN 2000:9914 USPATFULL
TI Integrin antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017925 20000125
AI US 1998-6626 19980113 (9)
PRAI US 1997-35614P 19970117 (60)
US 1997-62594P 19971020 (60)
DT Utility
FS Granted
LN.CNT 1601
INCL INCLM: 514/300.000
INCLS: 514/394.000; 514/562.000; 514/564.000; 514/565.000; 546/122.000; 548/304.400; 560/013.000; 560/035.000; 560/041.000; 562/427.000; 562/444.000; 562/450.000
NCL NCLM: 514/300.000
NCLS: 514/394.000; 514/562.000; 514/564.000; 514/565.000; 546/122.000; 548/304.400; 560/013.000; 560/035.000; 560/041.000; 562/427.000; 562/444.000; 562/450.000
IC [6]
ICM: A61K031-435
ICS: C07D471-04
EXF 546/122; 562/427; 548/304.4; 514/300; 514/394
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 28 OF 28 USPATFULL
AN 1998:61645 USPATFULL
TI Benzothiophene compounds and methods of use
IN Bryant, Henry Uhlman, Indianapolis, IN, United States
Cullinan, George Joseph, Trafalgar, IN, United States
Fahey, Kennan Joseph, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760030 19980602

pct/09885247

AI US 1997-886575 19970630 (8)
DT Utility
FS Granted
LN.CNT 1058
INCL INCLM: 514/213.000
INCLS: 514/324.000; 514/422.000; 514/444.000; 540/596.000; 546/202.000; 548/527.000; 549/051.000; 549/057.000
NCL NCLM: 514/217.030
NCLS: 514/324.000; 514/422.000; 514/444.000; 540/596.000; 546/202.000; 548/527.000; 549/051.000; 549/057.000
IC [6]
ICM: A61K031-38
ICS: A61K031-44; C07D409-00; C07D411-00
EXF 546/202; 514/324; 514/422; 514/213; 514/444; 548/527; 540/596; 549/51; 549/57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l1 27-28 kwic

L1 ANSWER 27 OF 28 USPATFULL
AB . . . dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, viral disease, and tumor growth.
SUMM . . . .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, viral disease, and tumor growth.
SUMM . . . been found to be useful in treating and/or inhibiting restenosis (recurrence of stenosis after corrective surgery on the heart valve), **atherosclerosis**, diabetic retinopathy, macular degeneration and angiogenesis (formation of new blood vessels), and inhibiting viral disease. Moreover, it has been postulated. . .
SUMM . . . antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation and tumor growth.
SUMM . . . the invention to identify .alpha.v.beta.3 antagonist compounds which are useful agents for inhibiting: bone resorption mediated by osteoclast cells, restenosis, **atherosclerosis**, inflammation, diabetic retinopathy, macular degeneration and angiogenesis in animals, preferably mammals, especially humans. Still another object of the invention is. . .
SUMM . . . .alpha.v.beta.3 ligands of the present invention are also useful for treating and/or inhibiting restenosis, diabetic retinopathy, macular degeneration, viral disease, **atherosclerosis** and/or angiogenesis in mammals.
DETD . . . of the compounds described above. Preferably, the condition is selected from bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis** , inflammation, viral disease, cancer and tumor growth. More preferably, the condition is selected from osteoporosis and cancer. Most preferably, the. . .
DETD . . . antagonizing effect; more specifically the .alpha.v.beta.3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of **atherosclerosis**, inhibition of angiogenesis, inhibition of diabetic retinopathy,

pct/09885247

```
       inhibition of macular degeneration, inhibition of inflammation,
       inhibition of viral disease, or inhibition.  .  .  is an .alpha.v.beta.5
       antagonizing effect or a dual .alpha.v.beta.3/.alpha.v.beta.5
       antagonizing effect. Examples of .alpha.v.beta.5 antagonizing effects
       are inhibition of: restenosis, atherosclerosis, angiogenesis,
       diabetic retinopathy, macular degeneration, inflammation, or tumor
       growth. Examples of dual .alpha.v.beta.3/.alpha.v.beta.5 antagonizing
       effects are inhibition of: bone resorption, restenosis,
       atherosclerosis, angiogenesis, diabetic retinopathy, macular
       degeneration, inflammation, viral disease, or tumor growth.
DETD   Nonlimiting examples of estrogen receptor modulators include estrogen,
       progesterin, estradiol, raloxifene, and tamoxifene.

L1   ANSWER 28 OF 28  USPATFULL
SUMM   .  .  .  the older, postmenopausal population. Current chemotherapy of
       these cancers have relied heavily on the use of anti-estrogen compounds,
       such as tamoxifene. Although such mixed agonist-antagonists
       have beneficial effects in the treatment of these cancers, and the
       estrogenic side-effects are tolerable in.  .  .
SUMM   Smooth muscle cell proliferation plays an important role in diseases
       such as atherosclerosis and restenosis. Vascular restenosis
       after percutaneous transluminal coronary angioplasty (PTCA) has been
       shown to be a tissue response characterized by.  .  .


=> s tamoxifene and atherosclerosis/cls
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
'CLS' IS NOT A VALID FIELD CODE
L2          0 TAMOXIFENE AND ATHEROSCLEROSIS/CLS
```

pct/09885247

```
=> s tamoxifene and atherosclerosis/clm
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
L3           1 TAMOXIFENE AND ATHEROSCLEROSIS/CLM

=> d l3

L3   ANSWER 1 OF 1  USPATFULL
AN      2001:237948  USPATFULL
TI      METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED
        DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES
IN      CHWALISZ, KRISTOF, BERLIN, Germany, Federal Republic of
        GARFIELD, ROBERT E., FRIENDSWOOD, TX, United States
        SHI, SHAO-QUING, GALVESTON, TX, United States
PI      US 2001056068      A1   20011227
AI      US 1998-34351      A1   19980304 (9)
DT      Utility
FS      APPLICATION
LN.CNT 1391
INCL    INCLM: 514/021.000
NCL     NCLM:  514/021.000
IC      [7]
        ICM: A61K038-00
        ICS: A61K031-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l3 1 kwic, ab

L3   ANSWER 1 OF 1  USPATFULL
```

pct/09885247

SUMM [0101] Partial estrogens: Raloxifene (Eli Lilly) (daily dose 0.1-600 mg/day orally, preferably 10-100 mg), **tamoxifene** at a daily dose of 1-200 mg/day orally, levormeloxifene (Novo-Nordisk) at a daily dose of 1-200 mg/day orally, clomiphene citrate at a daily dose of 1-200 mg, zuclomiphene citrate at a daily dose of 1-200 mg, droloxifene (3-hydroxy **tamoxifene**), CP 336 156 (Pfizer/Klinge), Idoxifene (Smith Kline) and RU 39 411 at equivalent doses.

CLM What is claimed is:
3. The method of claim 1, wherein the disease is **atherosclerosis** , restenosis, hypertension, preeclampsia and/or intrauterine fetal growth retardation.

AB The invention provides methods for control, management, treatment and prevention of conditions related to nitric oxide deficiency such as hypertension, cardiovascular disease, osteoporosis, diabetes mellitus, preeclampsia HELLP, syndrome and fetal growth retardation; uterine contractility disorders such as preterm labor and dysmenorrhea, cervical dystocia, infertility and early pregnancy loss; male impotence; urinary incontinence; intestinal tract disorders (e.g. altered motility and pyloric stenosis), respiratory system diseases (e.g. asthma, neonatal respiratory distress syndrome, pulmonary hypertension, and adult respiratory distress syndrome); inflammatory diseases (e.g. acute inflammation, resistance to infection, SLE-lupus, anaphylactic reaction, allograft rejection); Alzheimer's disease, stroke, growth hormone disorders, and behavior changes; dermatological conditions such as atopic eczema, topical hair loss, and burn injury; by administering citrulline or a citrulline analogue, optionally in combination with other enhancing or modulating agents, e.g., an estrogenic, partial estrogenic, progestagenic, or androgenic agent, and pharmaceutical preparations for such uses.

```
=> s tamoxifene and vascular
L4          93 TAMOXIFENE AND VASCULAR

=> s tamoxifene and vascular/clm
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
```

```
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
'CLM' IS NOT A VALID FIELD CODE
L5            2 TAMOXIFENE AND VASCULAR/CLM

=> s l5 1-2
MISSING OPERATOR L5 1-2
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l5 1-2

L5   ANSWER 1 OF 2  USPATFULL
AN      2002:126014  USPATFULL
TI      Formulation for topical non-invasive application in vivo
IN      Cevc, Gregor, Kirchheim, GERMANY, FEDERAL REPUBLIC OF
PI      US 2002064524       A1   20020530
AI      US 2001-887493      A1   20010622 (9)
RLI     Continuation of Ser. No. WO 1998-EP8421, filed on 23 Dec 1998, UNKNOWN
DT      Utility
FS      APPLICATION
LN.CNT 1846
INCL    INCLM: 424/094.630
        INCLS: 514/012.000; 514/054.000
NCL     NCLM:  424/094.630
        NCLS:  514/012.000; 514/054.000
IC      [7]
        ICM: A61K038-48
        ICS: A61K031-715; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 2 OF 2  USPATFULL
AN      2001:121485  USPATFULL
TI      Integrin receptor antagonists
IN      Duggan, Mark E., Schwenksville, PA, United States
        Meissner, Robert S., Schwenksville, PA, United States
        Perkins, James J., Churchville, PA, United States
PA      Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI      US 6268378          B1   20010731
AI      US 2000-498895           20000207 (9)
RLI     Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented,
        Pat. No. US 6066648, issued on 23 May 2000
PRAI    US 1997-69910P      19971217 (60)
        US 1998-83251P      19980427 (60)
        US 1998-92588P      19980713 (60)
DT      Utility
FS      GRANTED
LN.CNT 4460
INCL    INCLM: 514/300.000
        INCLS: 546/122.000
NCL     NCLM:  514/300.000
        NCLS:  546/122.000
IC      [7]
        ICM: A61K031-4375
        ICS: C07D471-04
EXF     546/122; 514/300
```

pct/09885247

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l5 2 kwic

L5 ANSWER 2 OF 2 USPATFULL

DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .

CLM What is claimed is:

. . . agent, d) a matrix metalloproteinase inhibitor, e) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f) an inhibitor of **vascular** endothelial growth factor, g) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna endothelial. . .

. . . agent, b) a matrix metalloproteinase inhibitor, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, d) an inhibitor of **vascular** endothelial growth factor, and e) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna. . .

pct/09885247

=> d l5 1-2

L5 ANSWER 1 OF 2 USPATFULL
AN 2002:126014 USPATFULL
TI Formulation for topical non-invasive application in vivo
IN Cevc, Gregor, Kirchheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2002064524 A1 20020530
AI US 2001-887493 A1 20010622 (9)
RLI Continuation of Ser. No. WO 1998-EP8421, filed on 23 Dec 1998, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 1846
INCL INCLM: 424/094.630
INCLS: 514/012.000; 514/054.000
NCL NCLM: 424/094.630
NCLS: 514/012.000; 514/054.000
IC [7]
ICM: A61K038-48
ICS: A61K031-715; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 2 USPATFULL
AN 2001:121485 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6268378 B1 20010731
AI US 2000-498895 20000207 (9)
RLI Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS GRANTED
LN.CNT 4460
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A61K031-4375
ICS: C07D471-04
EXF 546/122; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l5 2 kwic

L5 ANSWER 2 OF 2 USPATFULL
DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**
.
CLM What is claimed:
. . . agent, d) a matrix metalloproteinase inhibitor, e) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f) an inhibitor of **vascular** endothelial growth

factor, g) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna endothelial. . .
. . . agent, b) a matrix metalloproteinase inhibitor, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, d) an inhibitor of **vascular** endothelial growth factor, and e) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna. . .

=> d his

(FILE 'HOME' ENTERED AT 14:21:25 ON 27 JUN 2002)

FILE 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, PASCAL, ...' ENTERED AT 14:21:53 ON 27 JUN 2002

L1 28 S TAMOXIFENE AND ATHEROSCLEROSIS
L2 0 S TAMOXIFENE AND ATHEROSCLEROSIS/CLS
L3 1 S TAMOXIFENE AND ATHEROSCLEROSIS/CLM
L4 93 S TAMOXIFENE AND VASCULAR
L5 2 S TAMOXIFENE AND VASCULAR/CLM

=> s 14 and cholesterol
L6 17 L4 AND CHOLESTEROL

=> d l6 1-17 bib, ab, kwic

L6 ANSWER 1 OF 17 USPATFULL
AN 2002:152632 USPATFULL
TI .alpha.v integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6410526 B1 20020625
AI US 2000-583522 20000531 (9)
PRAI US 1999-137101P 19990602 (60)
US 2000-179216P 20000131 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3656
AB The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
AB . . . of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5

and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

SUMM . . . .alpha.v integrin receptors associated with other .beta.-subunits, and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha.v.beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha.v.beta.3 antagonists which inhibit angiogenesis may represent a novel. . .

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, cancer, and metastatic tumor growth.

SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**Vascular** Indications for Integrin .alpha.v Antagonists," Curr. Pharmaceut. Design 3: 545-584 (1997)). A benzazepine nucleus has been employed among others by. . .

DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .

DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 2 OF 17 USPATFULL
AN 2002:67236 USPATFULL
TI Alpha V integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Perkins, James J., Churchville, PA, UNITED STATES
Steele, Thomas G., Schwenksville, PA, UNITED STATES
Wang, Jiabing, Chalfont, PA, UNITED STATES
Patane, Michael A., Billerica, MA, UNITED STATES
PI US 2002037889 A1 20020328
AI US 2001-766148 A1 20010119 (9)
PRAI US 2000-177168P 20000120 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor

antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

AB . . . of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

SUMM . . . .alpha.v integrin receptors associated with other .beta.-subunits, and are useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha.v.beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha.v.beta.3 antagonists which inhibit angiogenesis may represent a novel. . .

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**Vascular** Indications for Integrin .alpha.v Antagonists," Curr. Pharmaceut. Design 3: 545-584 (1997)). A benzazepine nucleus has been employed among others by. . . .

SUMM [0216] Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**.

SUMM . . . the bone-resorbing activity of isolated mature rabbit osteoclasts via binding to its receptors on osteoclasts (see M. Nakagawa et al., "**Vascular** endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts," FEBS Letters, 473: 161-164 (2000)). Therefore,. . . .

SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 3 OF 17 USPATFULL
AN 2002:57802 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
Ihle, Nathan, Mercer Island, WA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6358970 B1 20020319
AI US 2000-599088 20000621 (9)
PRAI US 1999-140535P 19990623 (60)
DT Utility

pct/09885247

FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
AB . . . of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
SUMM . . . .alpha.v integrin receptors associated with other .beta.-subunits, and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha.v.beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha.v.beta.3 antagonists which inhibit angiogenesis may represent a novel. . .
SUMM . . . These compounds, referred to as "dual .beta.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, cancer, and metastatic tumor growth.
SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**Vascular** Indications for Integrin .alpha.v Antagonists," Curr. Pharmaceut. Design 3: 545-584 (1997)). A benzazepine nucleus has been employed among others by. . .
DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .
DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 4 OF 17 USPATFULL
AN 2002:17296 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES

Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES

PI US 2002010176 A1 20020124
AI US 2001-916977 A1 20010728 (9)
RLI Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING
Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

SUMM . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, tumor growth, and metastasis.

SUMM [1130] Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**.

SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 5 OF 17 USPATFULL

pct/09885247

AN 2001:233621 USPATFULL
TI Alpha V integrin receptor antagonists
IN Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States
PI US 2001053853 A1 20011220
AI US 2001-767471 A1 20010123 (9)
PRAI US 2000-177792P 20000124 (60)
US 2000-230469P 20000906 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
AB . . . of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
SUMM . . . .alpha.v integrin receptors associated with other .beta.-subunits, and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha.v.beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha.v.beta.3 antagonists which inhibit angiogenesis may represent a novel. . .
SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**Vascular** Indications for Integrin .alpha.v Antagonists," Curr. Pharmaceut. Design 3: 545-584 (1997)). A benzazepine nucleus has been employed among others by. . .
SUMM [0333] Nonlimiting examples of estrogen receptor modulators include

estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**.

SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 6 OF 17 USPATFULL
AN 2001:168133 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6297249 B1 20011002
AI US 1999-453847 19991202 (9)
RLI Division of Ser. No. US 1998-212082, filed on 15 Dec 1998
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

SUMM . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, tumor growth, and metastasis.

SUMM Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**.

SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 7 OF 17 USPATFULL
AN 2001:121485 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6268378 B1 20010731
AI US 2000-498895 20000207 (9)
RLI Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Solola, Taofiq A.
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
AB . . . of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
SUMM . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . These compounds, referred to as "dual .alpha..nu..beta.3/.alpha..nu..beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.
DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .
DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or

phosphatidylcholines.
CLM What is claimed is:
. . . agent, d) a matrix metalloproteinase inhibitor, e) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f) an inhibitor of **vascular** endothelial growth factor, g) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna endothelial. . .
. . . agent, b) a matrix metalloproteinase inhibitor, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, d) an inhibitor of **vascular** endothelial growth factor, and e) an inhibitor of fetal liver kinase-1/kinase insert domain-containing receptor, fms oncogene-like tyrosine kinase, tunica interna. . .

L6 ANSWER 8 OF 17 USPATFULL
AN 2001:71543 USPATFULL
TI Bezazepine derivatives as .alpha.v integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6232308 B1 20010515
AI US 2000-496525 20000202 (9)
PRAI US 1999-118428P 19990203 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to benzazepine derivatives and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, tumor growth, and metastasis.
SUMM Nonlimiting examples of estrogen receptor modulators include estrogen,

progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**
.

SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 9 OF 17 USPATFULL
AN 2001:48064 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6211191 B1 20010403
AI US 1998-212510 19981215 (9)
PRAI US 1997-69909P 19971217 (60)
US 1998-83250P 19980427 (60)
US 1998-92630P 19980713 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Jayaram, Beby
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
AB . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . These compounds, referred to as "dual .alpha..nu..beta.3/.alpha..nu..beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.
SUMM Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**
.
SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of

phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 10 OF 17 USPATFULL
AN 2000:92099 USPATFULL
TI Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
IN Hutchinson, John H., Philadelphia, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6090944 20000718
AI US 1999-371444 19990810 (9)
PRAI US 1998-96378P 19980813 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.
LREP Durette, Philippe L., Winokur, Melvin
CLMN Number of Claims: 36
ECL Exemplary Claim: 1,24
DRWN No Drawings
LN.CNT 3589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.
AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.
SUMM . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, tumor growth, and metastasis.
SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha..nu..beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha..nu..beta.3 antagonists which inhibit angiogenesis may represent a novel. . .
SUMM . . . These compounds, referred to as "dual .alpha..nu..beta.3/.alpha..nu..beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, tumor growth, and metastasis.
SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**Vascular** Indications for Integrin .alpha..nu.Antagonists," Curr. Pharmaceut. Design 3: 545-584(1997)). A benzazepine nucleus has been employed among others by Genentech and. . .
SUMM Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**

.
SUMM . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 11 OF 17 USPATFULL
AN 2000:64874 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6066648 20000523
AI US 1998-212123 19981215 (9)
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Keating, Dominic
LREP Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
AB . . . of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
SUMM . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . These compounds, referred to as "dual .alpha..nu..beta.3/.alpha..nu..beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.
DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene**
.
DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

pct/09885247

L6 ANSWER 12 OF 17 USPATFULL
AN 2000:44101 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6048861 20000411
AI US 1998-212082 19981215 (9)
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.
LREP Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, tumor growth, and metastasis.
DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .

DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 13 OF 17 USPATFULL
AN 2000:34557 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6040311 20000321
AI US 1999-362528 19990728 (9)
PRAI US 1998-94478P 19980729 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.
AB . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.
SUMM . . . the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, tumor growth, and metastasis.
SUMM . . . been presented suggesting that angiogenesis is a central factor in the initiation and persistence of arthritic disease, and that the **vascular** integrin .alpha..nu..beta.3 may be a preferred target in inflammatory arthritis. Therefore, .alpha..nu..beta.3 antagonists which inhibit angiogenesis may represent a novel. . .
SUMM . . . These compounds, referred to as "dual .alpha..nu..beta.3/.alpha..nu..beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, tumor growth, and metastasis.
SUMM . . . receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "**vascular** Indications for Integrin .alpha..nu. Antagonists," Curr. Pharmaceut. Design 3: 545-584(1997)). A benzazepine nucleus has been employed among others by Genentech. . .

DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .

DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 14 OF 17 USPATFULL
AN 2000:9915 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017926 20000125
AI US 1998-212079 19981215 (9)
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
US 1998-79197P 19980324 (60)
US 1998-79944P 19980330 (60)
US 1998-80397P 19980402 (60)
US 1998-92624P 19980713 (60)
US 1998-99948P 19980911 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
AB . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
SUMM . . . the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

pct/09885247

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.

DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and **tamoxifene** .

DETD . . . small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 15 OF 17 USPATFULL
AN 2000:9914 USPATFULL
TI Integrin antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017925 20000125
AI US 1998-6626 19980113 (9)
PRAI US 1997-35614P 19970117 (60)
US 1997-62594P 19971020 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Durette, Philippe L., Sabatelli, Anthony D., Winokur, Melvin
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

SUMM . . . are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

SUMM . . . These compounds, referred to as "dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting **vascular** restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

DETD Further illustrative are methods of inhibiting angiogenesis comprising administering a compound as described above in combination with a VEGF (a **vascular** endothethial growth factor) inhibitor compound. Such combinations are useful for treating disease states such as macular degeneration, diabetic retinopathy, and. . .

DETD Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, raloxifene, and **tamoxifene**.

DETD . . . small unilamellar vesicles, large unilamellar vesicles and

multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as **cholesterol**, stearylamine or phosphatidylcholines.

L6 ANSWER 16 OF 17 USPATFULL
AN 1998:61645 USPATFULL
TI Benzothiophene compounds and methods of use
IN Bryant, Henry Uhlman, Indianapolis, IN, United States
Cullinan, George Joseph, Trafalgar, IN, United States
Fahey, Kennan Joseph, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760030 19980602
AI US 1997-886575 19970630 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Kifle, Bruck
LREP Strode, Janelle D., Boone, David E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention provides novel benzothiophene compounds, pharmaceutical formulations, and methods of use.
SUMM . . . to date indicates that estrogen can up regulate the low density lipid (LDL) receptors in the liver to remove excess **cholesterol** . Additionally, estrogen appears to have some effect on the biosynthesis of **cholesterol**, and other beneficial effects on cardiovascular health.
SUMM . . . the older, postmenopausal population. Current chemotherapy of these cancers have relied heavily on the use of anti-estrogen compounds, such as **tamoxifene**. Although such mixed agonist-antagonists have beneficial effects in the treatment of these cancers, and the estrogenic side-effects are tolerable in. . .
SUMM Smooth muscle cell proliferation plays an important role in diseases such as atherosclerosis and restenosis. **Vascular** restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by an early and. . . due to thrombosis with some vasospasms, while the late phase appears to be dominated by excessive proliferation and migration of **vascular** aortal smooth muscle cells. In this disease, the increased cell motility and colonization by such muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of **vascular** aortal smooth muscle cells may be the primary mechanism of the reocclusion of coronary arteries following PTCA, laser angioplasty, and. . .
SUMM **Vascular** restenosis remains a major long term complication following surgical intervention of blocked arteries by PTCA, atherectomy, laser angioplasty, and arterial. . . the patients who undergo PTCA, reocclusion occurs within three to six months after the procedure. The current strategies for treating **vascular** restenosis include mechanical intervention by devices such as agents or pharmacologic therapies including heparin, low molecular weight heparin, coumarin, aspirin,. . . prostacyclin. These strategies have failed to curb the reocclusion rate and have been ineffective for the treatment and prevention of **vascular** restenosis. (See: "Prevention of Restenosis after Percutaneous Transluminal Coronary Angioplasty: The Search for a `Magic Bullet`", Hermans et al., American. . .
SUMM . . . constituents in the blood and in the damaged arterial vessel

wall which mediate the proliferation of smooth muscle cells in **vascular** restenosis. Agents that inhibit the proliferation and/or migration of smooth aortal muscle cells are useful in the treatment and prevention. . .

DETD . . . with 17-.alpha.-ethynyl estradiol (EE.sub.2), and rats treated with certain compounds of this invention. Although EE.sub.2 caused a decrease in serum **cholesterol** when orally administered at 0.1 mg/kg/day, it also exerted a stimulatory effect on the uterus so that EE.sub.2 uterine weight. . .

DETD Not only did the compounds of the present invention reduce serum **cholesterol** compared to the ovariectomized animals, but the uterine weight was increased to lesser extent than those given EE.sub.2. Compared to estrogenic compounds known in the art, the benefit of serum **cholesterol** reduction while lessening the effect on uterine weight is unusual and desirable.

DETD . . . 47.0* 69.1*

.sup.a mg/kg PO
.sup.b Uterine Weight % increase versus the ovarierectomized controls
.sup.c Eoslnophil peroxidase, V.sub.maximum
.sup.d Serum **cholesterol** decrease versus ovariectomized controls
*p < .05

DETD A baseline examination of each patient would include serum determination of **cholesterol** and triglyceride levels. At the end of the study period (six months), each patient would have their serum lipid profile taken. Analysis of the data would confirm a lowering of the serum lipids, for example, **cholesterol** and/or triglycerides, in the test group versus the control.

L6 ANSWER 17 OF 17 USPATFULL
AN 96:97050 USPATFULL
TI Hypoglycemic agents
IN Cullinan, George J., Trafalgar, IN, United States
Yen, Terence T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5567713 19961022
AI US 1995-370062 19950109 (8)
RLI Division of Ser. No. US 1993-82218, filed on 24 Jun 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Sales, James J., Demeter, John C., Boone, David E.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for treating hyperglycemia in mammals by administering an antiestrogen compound and pharmaceutically acceptable salts and solvates thereof.

SUMM . . . standing diabetes. These symptoms include degeneration of the walls of blood vessels. Although many different organs are affected by these **vascular** changes, the nerves, eyes and kidneys appear to be the most susceptible. As such, long-standing diabetes mellitus, even when treated. . .

SUMM . . . of juvenile onset, ketosis-prone, develops early in life with much more severe symptoms and has a near-certain prospect of later **vascular** involvement. Control of this type of diabetes is difficult and requires exogenous insulin administration. Type II

diabetes mellitus, is of. . .

DETD . . . 39(4), 911 (1991) which are all incorporated by reference herein, in their entirety. Specific illustrative compounds within this class include **Tamoxifene**, Clomiphene and (Z) -4-[1-[4-[2-dimethylamino)ethoxy]phenyl]-2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate.

DETD U.S. Pat. No. 4,536,516 describes **Tamoxifene**, a triarylethylene having the formula ##STR2## and pharmaceutically acceptable acid addition salts and solvates thereof, and discloses methods of synthesis.

DETD . . . clot at room temperature for 2 hrs, and serum is obtained following centrifugation for 10 min at 3000 rpm. Serum **cholesterol** is determined using a Boehringer Mannhelm Diagnostics high performance **cholesterol** assay. Briefly, the **cholesterol** is oxidized to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide was then reacted with phenol and 4-aminophenazone in the presence of peroxidase to produce a p-quinone imine dye, which is read spectrophotemetrically at 500 nm. **Cholesterol** concentration is then calculated against a standard curve. The entire assay is automated using a Biomek Automated Workstation.

DETD Ovariectomy of the rats caused an increase in serum **cholesterol** as compared to intact vehicle treated controls. Estrogen, administered in the orally active form of ethynyl estradiol (EE.sub.2), causes a decrease in serum **cholesterol** in a dose dependent manner, but it also exerts a stimulatory action on the uterus resulting in uterine weights approaching. . .

=>

y action on the uterus resulting in uterine
weights approaching. . .

```
=> file uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   109.32     109.53

FILE 'USPATFULL' ENTERED AT 14:36:20 ON 27 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Jun 2002 (20020627/PD)
FILE LAST UPDATED: 27 Jun 2002 (20020627/ED)
HIGHEST GRANTED PATENT NUMBER: US6412112
HIGHEST APPLICATION PUBLICATION NUMBER: US2002083506
CA INDEXING IS CURRENT THROUGH 27 Jun 2002 (20020627/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Jun 2002 (20020627/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2002

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together         <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to           <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s atherosclereosis and tamoxifene
             2 ATHEROSCLEREOSIS
            47 TAMOXIFENE
L7           0 ATHEROSCLEREOSIS AND TAMOXIFENE

=> s atherosclerosis and tamoxifene
         10584 ATHEROSCLEROSIS
            47 TAMOXIFENE
L8          19 ATHEROSCLEROSIS AND TAMOXIFENE

=> s l8 and pd<1999
       2432548 PD<1999
                  (PD<19990000)
L9           1 L8 AND PD<1999

=> d l9 bib, ab, kwic
```

L9 ANSWER 1 OF 1 USPATFULL
AN 1998:61645 USPATFULL
TI Benzothiophene compounds and methods of use
IN Bryant, Henry Uhlman, Indianapolis, IN, United States
Cullinan, George Joseph, Trafalgar, IN, United States
Fahey, Kennan Joseph, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760030 19980602 <--
AI US 1997-886575 19970630 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Kifle, Bruck
LREP Strode, Janelle D., Boone, David E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention provides novel benzothiophene compounds, pharmaceutical formulations, and methods of use.
PI US 5760030 19980602 <--
SUMM . . . the older, postmenopausal population. Current chemotherapy of these cancers have relied heavily on the use of anti-estrogen compounds, such as **tamoxifene**. Although such mixed agonist-antagonists have beneficial effects in the treatment of these cancers, and the estrogenic side-effects are tolerable in. . .
SUMM Smooth muscle cell proliferation plays an important role in diseases such as **atherosclerosis** and restenosis. Vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by. . .

=> d his

(FILE 'HOME' ENTERED AT 14:21:25 ON 27 JUN 2002)

FILE 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, PASCAL, ...' ENTERED AT 14:21:53 ON 27 JUN 2002
L1 28 S TAMOXIFENE AND ATHEROSCLEROSIS
L2 0 S TAMOXIFENE AND ATHEROSCLEROSIS/CLS
L3 1 S TAMOXIFENE AND ATHEROSCLEROSIS/CLM
L4 93 S TAMOXIFENE AND VASCULAR
L5 2 S TAMOXIFENE AND VASCULAR/CLM
L6 17 S L4 AND CHOLESTEROL

FILE 'USPATFULL' ENTERED AT 14:36:20 ON 27 JUN 2002
L7 0 S ATHEROSCLEREOSIS AND TAMOXIFENE
L8 19 S ATHEROSCLEROSIS AND TAMOXIFENE
L9 1 S L8 AND PD<1999

=> d l8 1-19

L8 ANSWER 1 OF 19 USPATFULL
AN 2002:152632 USPATFULL
TI .alpha.v integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States

Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6410526 B1 20020625
AI US 2000-583522 20000531 (9)
PRAI US 1999-137101P 19990602 (60)
US 2000-179216P 20000131 (60)
DT Utility
FS GRANTED
LN.CNT 3656
INCL INCLM: 514/212.020
INCLS: 514/212.060; 514/215.000; 540/521.000; 540/543.000; 540/577.000; 540/580.000
NCL NCLM: 514/212.020
NCLS: 514/212.060; 514/215.000; 540/521.000; 540/543.000; 540/577.000; 540/580.000
IC [7]
ICM: A61K031-55
ICS: C07D487-02; A61P019-10
EXF 514/212.02; 514/212.06; 514/215; 540/521; 540/543; 540/577; 540/580

L8 ANSWER 2 OF 19 USPATFULL
AN 2002:92700 USPATFULL
TI Alpha v integrin receptor antagonists
IN Arison, Byron H., Watchung, NJ, UNITED STATES
Cui, Donghui, Newton, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Subramanian, Raju, Perkasie, PA, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES
PI US 2002049224 A1 20020425
AI US 2001-952084 A1 20010914 (9)
PRAI US 2000-232344P 20000914 (60)
DT Utility
FS APPLICATION
LN.CNT 1088
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A61K031-4745
ICS: C07D471-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 19 USPATFULL
AN 2002:72890 USPATFULL
TI Alpha V integrin receptor antagonists
IN Coleman, Paul J., Wallingford, PA, UNITED STATES
Cui, Donghui, Newtown, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Landsdale, PA, UNITED STATES
Silva Elipe, Maria Victoria, Mountainside, NJ, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES
PI US 2002040030 A1 20020404
AI US 2001-953606 A1 20010914 (9)

pct/09885247

PRAI US 2000-232262P 20000914 (60)
DT Utility
FS APPLICATION
LN.CNT 1296
INCL INCLM: 514/256.000
INCLS: 544/333.000
NCL NCLM: 514/256.000
NCLS: 544/333.000
IC [7]
ICM: C07D043-14
ICS: A61K031-506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 19 USPATFULL
AN 2002:67236 USPATFULL
TI Alpha V integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Perkins, James J., Churchville, PA, UNITED STATES
Steele, Thomas G., Schwenksville, PA, UNITED STATES
Wang, Jiabing, Chalfont, PA, UNITED STATES
Patane, Michael A., Billerica, MA, UNITED STATES
PI US 2002037889 A1 20020328
AI US 2001-766148 A1 20010119 (9)
PRAI US 2000-177168P 20000120 (60)
DT Utility
FS APPLICATION
LN.CNT 2835
INCL INCLM: 514/214.010
INCLS: 514/256.000; 514/278.000; 514/300.000; 514/340.000
NCL NCLM: 514/214.010
NCLS: 514/256.000; 514/278.000; 514/300.000; 514/340.000
IC [7]
ICM: A61K031-55
ICS: A61K031-505; A61K031-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 19 USPATFULL
AN 2002:57802 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
Ihle, Nathan, Mercer Island, WA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6358970 B1 20020319
AI US 2000-599088 20000621 (9)
PRAI US 1999-140535P 19990623 (60)
DT Utility
FS GRANTED
LN.CNT 2558
INCL INCLM: 514/300.000
INCLS: 514/253.000; 540/597.000; 544/362.000; 546/122.000
NCL NCLM: 514/300.000
NCLS: 514/253.040; 540/597.000; 544/362.000; 546/122.000
IC [7]
ICM: A61K031-435

ICS: C07D471-04
EXF 546/122; 544/362; 514/300; 514/253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 19 USPATFULL
AN 2002:17296 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES
PI US 2002010176 A1 20020124
AI US 2001-916977 A1 20010728 (9)
RLI Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING
Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS APPLICATION
LN.CNT 5336
INCL INCLM: 514/224.200
INCLS: 514/227.500; 514/238.200; 514/249.000; 514/252.120; 514/256.000; 514/258.000; 514/277.000; 514/412.000; 514/359.000; 514/550.000; 514/551.000; 560/149.000; 560/168.000; 548/570.000; 548/452.000; 546/341.000; 546/329.000; 544/399.000; 544/349.000
NCL NCLM: 514/224.200
NCLS: 514/227.500; 514/238.200; 514/249.000; 514/252.120; 514/256.000; 514/258.000; 514/277.000; 514/412.000; 514/359.000; 514/550.000; 514/551.000; 560/149.000; 560/168.000; 548/570.000; 548/452.000; 546/341.000; 546/329.000; 544/399.000; 544/349.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-495; C07D211-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 19 USPATFULL
AN 2001:237948 USPATFULL
TI METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES
IN CHWALISZ, KRISTOF, BERLIN, Germany, Federal Republic of
GARFIELD, ROBERT E., FRIENDSWOOD, TX, United States
SHI, SHAO-QUING, GALVESTON, TX, United States
PI US 2001056068 A1 20011227
AI US 1998-34351 A1 19980304 (9)
DT Utility
FS APPLICATION
LN.CNT 1391
INCL INCLM: 514/021.000
NCL NCLM: 514/021.000
IC [7]

ICM: A61K038-00
ICS: A61K031-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 19 USPATFULL
AN 2001:233621 USPATFULL
TI Alpha V integrin receptor antagonists
IN Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States
PI US 2001053853 A1 20011220
AI US 2001-767471 A1 20010123 (9)
PRAI US 2000-177792P 20000124 (60)
US 2000-230469P 20000906 (60)
DT Utility
FS APPLICATION
LN.CNT 4132
INCL INCLM: 544/295.000
INCLS: 544/296.000; 544/333.000
NCL NCLM: 544/295.000
NCLS: 544/296.000; 544/333.000
IC [7]
ICM: C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 19 USPATFULL
AN 2001:168133 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6297249 B1 20011002
AI US 1999-453847 19991202 (9)
RLI Division of Ser. No. US 1998-212082, filed on 15 Dec 1998
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS GRANTED
LN.CNT 4784
INCL INCLM: 514/256.000
INCLS: 514/302.000; 514/352.000; 544/333.000; 546/115.000; 546/312.000
NCL NCLM: 514/256.000
NCLS: 514/302.000; 514/352.000; 544/333.000; 546/115.000; 546/312.000
IC [7]
ICM: C07D401-06
ICS: C07D213-55; A61K031-444
EXF 544/333; 546/115; 546/312; 514/256; 514/302; 514/352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 19 USPATFULL
AN 2001:121485 USPATFULL
TI Integrin receptor antagonists

IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6268378 B1 20010731
AI US 2000-498895 20000207 (9)
RLI Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS GRANTED
LN.CNT 4460
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A61K031-4375
ICS: C07D471-04
EXF 546/122; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 19 USPATFULL
AN 2001:71543 USPATFULL
TI Bezazepine derivatives as .alpha.v integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6232308 B1 20010515
AI US 2000-496525 20000202 (9)
PRAI US 1999-118428P 19990203 (60)
DT Utility
FS Granted
LN.CNT 1967
INCL INCLM: 514/221.000
INCLS: 540/504.000; 540/509.000; 540/510.000; 540/511.000; 540/491.000; 540/523.000; 514/211.050; 514/212.070
NCL NCLM: 514/221.000
NCLS: 514/211.050; 514/212.070; 540/491.000; 540/504.000; 540/509.000; 540/510.000; 540/511.000; 540/523.000
IC [7]
ICM: A61K031-5513
ICS: C07D243-14; C07D471-04; C07D471-14
EXF 540/504; 540/509; 540/510; 540/511; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 19 USPATFULL
AN 2001:48064 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6211191 B1 20010403
AI US 1998-212510 19981215 (9)
PRAI US 1997-69909P 19971217 (60)
US 1998-83250P 19980427 (60)
US 1998-92630P 19980713 (60)
DT Utility

FS Granted
LN.CNT 3544
INCL INCLM: 514/274.000
INCLS: 544/296.000; 544/316.000; 562/013.000
NCL NCLM: 514/274.000
NCLS: 544/296.000; 544/316.000; 562/013.000
IC [7]
ICM: C07D403-06
ICS: C07D401-06; A61K031-506; A61P019-02; A61P035-00
EXF 562/13; 544/296; 544/316; 514/274
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 19 USPATFULL
AN 2000:92099 USPATFULL
TI Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
IN Hutchinson, John H., Philadelphia, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6090944 20000718
AI US 1999-371444 19990810 (9)
PRAI US 1998-96378P 19980813 (60)
DT Utility
FS Granted
LN.CNT 3589
INCL INCLM: 546/122.000
INCLS: 514/218.000; 514/252.000; 514/299.000; 514/300.000; 514/340.000; 514/390.000; 514/392.000; 540/492.000; 544/284.000; 546/122.000; 546/134.000; 546/274.000; 546/004.000; 546/300.000; 546/277.700; 548/304.700; 548/323.500; 548/324.500; 548/325.100
NCL NCLM: 546/122.000
NCLS: 540/492.000; 544/284.000; 546/004.000; 546/134.000; 546/274.400; 546/276.100; 546/277.700; 546/300.000; 548/304.700; 548/323.500; 548/324.500; 548/325.100
IC [7]
ICM: C07D471-02
ICS: C07D453-02; C07D401-06; A61K031-4375; A61N019-08; A61N019-10
EXF 546/122; 546/274.4; 546/277.7; 544/284; 540/492; 548/304.7; 514/300; 514/218; 514/392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 19 USPATFULL
AN 2000:64874 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6066648 20000523
AI US 1998-212123 19981215 (9)
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
DT Utility
FS Granted
LN.CNT 4780
INCL INCLM: 514/300.000
INCLS: 546/122.000
NCL NCLM: 514/300.000
NCLS: 546/122.000
IC [7]
ICM: A01N043-40

ICS: C07D471-04
EXF 546/122; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 19 USPATFULL
AN 2000:44101 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6048861 20000411
AI US 1998-212082 19981215 (9)
PRAI US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)
DT Utility
FS Granted
LN.CNT 5443
INCL INCLM: 514/256.000
INCLS: 514/300.000; 544/333.000; 546/122.000; 546/123.000
NCL NCLM: 514/256.000
NCLS: 514/300.000; 544/333.000; 546/122.000; 546/123.000
IC [7]
ICM: C07D471-04
ICS: C07D401-06; C07D401-12; A61K031-44; A61K031-435
EXF 544/333; 546/122; 546/123; 514/256; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 19 USPATFULL
AN 2000:34557 USPATFULL
TI Integrin receptor antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6040311 20000321
AI US 1999-362528 19990728 (9)
PRAI US 1998-94478P 19980729 (60)
DT Utility
FS Granted
LN.CNT 2801
INCL INCLM: 514/275.000
INCLS: 514/300.000; 514/395.000; 514/398.000; 544/332.000; 546/122.000; 548/308.700; 548/321.500
NCL NCLM: 514/275.000
NCLS: 514/300.000; 514/395.000; 514/398.000; 544/332.000; 546/122.000; 548/308.700; 548/321.500
IC [7]
ICM: A61K031-505
ICS: A61K031-435; C07D239-42; C07D471-04
EXF 544/332; 546/122; 548/308.7; 548/321.5; 514/275; 514/300; 514/395;

514/398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 19 USPATFULL
AN 2000:9915 USPATFULL
TI Integrin receptor antagonists
IN Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017926 20000125
AI US 1998-212079 19981215 (9)
PRAI US 1997-69910P 19971217 (60)
US 1998-83251P 19980427 (60)
US 1998-92588P 19980713 (60)
US 1998-79197P 19980324 (60)
US 1998-79944P 19980330 (60)
US 1998-80397P 19980402 (60)
US 1998-92624P 19980713 (60)
US 1998-99948P 19980911 (60)
DT Utility
FS Granted
LN.CNT 5668
INCL INCLM: 514/300.000
INCLS: 514/230.500; 514/300.000; 514/333.000; 544/105.000; 544/335.000; 546/081.000; 546/082.000; 546/122.000; 546/256.000; 546/115.000; 546/118.000; 548/306.100
NCL NCLM: 514/300.000
NCLS: 514/230.500; 514/333.000; 544/105.000; 544/335.000; 546/081.000; 546/082.000; 546/115.000; 546/118.000; 546/122.000; 546/256.000; 548/306.100
IC [6]
ICM: A61K031-435
ICS: C07D471-04
EXF 546/122; 546/256; 546/81; 546/82; 544/105; 544/335; 548/306.1; 514/230.5; 514/333; 514/303; 514/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 19 USPATFULL
AN 2000:9914 USPATFULL
TI Integrin antagonists
IN Duggan, Mark E., Schwenksville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6017925 20000125
AI US 1998-6626 19980113 (9)
PRAI US 1997-35614P 19970117 (60)
US 1997-62594P 19971020 (60)
DT Utility
FS Granted
LN.CNT 1601
INCL INCLM: 514/300.000
INCLS: 514/394.000; 514/562.000; 514/564.000; 514/565.000; 546/122.000; 548/304.400; 560/013.000; 560/035.000; 560/041.000; 562/427.000; 562/444.000; 562/450.000
NCL NCLM: 514/300.000

NCLS: 514/394.000; 514/562.000; 514/564.000; 514/565.000; 546/122.000; 548/304.400; 560/013.000; 560/035.000; 560/041.000; 562/427.000; 562/444.000; 562/450.000
IC [6]
ICM: A61K031-435
ICS: C07D471-04
EXF 546/122; 562/427; 548/304.4; 514/300; 514/394
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 19 USPATFULL
AN 1998:61645 USPATFULL
TI Benzothiophene compounds and methods of use
IN Bryant, Henry Uhlman, Indianapolis, IN, United States
Cullinan, George Joseph, Trafalgar, IN, United States
Fahey, Kennan Joseph, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760030 19980602
AI US 1997-886575 19970630 (8)
DT Utility
FS Granted
LN.CNT 1058
INCL INCLM: 514/213.000
INCLS: 514/324.000; 514/422.000; 514/444.000; 540/596.000; 546/202.000; 548/527.000; 549/051.000; 549/057.000
NCL NCLM: 514/217.030
NCLS: 514/324.000; 514/422.000; 514/444.000; 540/596.000; 546/202.000; 548/527.000; 549/051.000; 549/057.000
IC [6]
ICM: A61K031-38
ICS: A61K031-44; C07D409-00; C07D411-00
EXF 546/202; 514/324; 514/422; 514/213; 514/444; 548/527; 540/596; 549/51; 549/57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l8 1-19 ab

L8 ANSWER 1 OF 19 USPATFULL
AB The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

L8 ANSWER 2 OF 19 USPATFULL
AB The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. ##STR1##

L8 ANSWER 3 OF 19 USPATFULL
AB The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R.dbd.H or Me), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. ##STR1##

L8 ANSWER 4 OF 19 USPATFULL
AB The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

L8 ANSWER 5 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

L8 ANSWER 6 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, tumor growth, and metastasis.

L8 ANSWER 7 OF 19 USPATFULL
AB The invention provides methods for control, management, treatment and prevention of conditions related to nitric oxide deficiency such as hypertension, cardiovascular disease, osteoporosis, diabetes mellitus, preeclampsia HELLP, syndrome and fetal growth retardation; uterine contractility disorders such as preterm labor and dysmenorrhea, cervical dystocia, infertility and early pregnancy loss; male impotence; urinary incontinence; intestinal tract disorders (e.g. altered motility and pyloric stenosis), respiratory system diseases (e.g. asthma, neonatal respiratory distress syndrome, pulmonary hypertension, and adult respiratory distress syndrome); inflammatory diseases (e.g. acute inflammation, resistance to infection, SLE-lupus, anaphylactic reaction, allograft rejection); Alzheimer's disease, stroke, growth hormone disorders, and behavior changes; dermatological conditions such as atopic eczema, topical hair loss, and burn injury; by administering citrulline or a citrulline analogue, optionally in combination with

other enhancing or modulating agents, e.g., an estrogenic, partial estrogenic, progestagenic, or androgenic agent, and pharmaceutical preparations for such uses.

L8 ANSWER 8 OF 19 USPATFULL
AB The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammatory arthritis, cancer, and metastatic tumor growth.

L8 ANSWER 9 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, tumor growth, and metastasis.

L8 ANSWER 10 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, viral disease, and tumor growth.

L8 ANSWER 11 OF 19 USPATFULL
AB The present invention relates to benzazepine derivatives and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, tumor growth, and metastasis.

L8 ANSWER 12 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, tumor growth, and metastasis.

L8 ANSWER 13 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof,

their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

L8 ANSWER 14 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, viral disease, and tumor growth.

L8 ANSWER 15 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, tumor growth, and metastasis.

L8 ANSWER 16 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

L8 ANSWER 17 OF 19 USPATFULL
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, **atherosclerosis**, inflammation, wound healing, viral disease, and tumor growth and metastasis.

L8 ANSWER 18 OF 19 USPATFULL
AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration,

angiogenesis, **atherosclerosis**, inflammation, viral disease, and tumor growth.

L8 ANSWER 19 OF 19 USPATFULL

AB The instant invention provides novel benzothiophene compounds, pharmaceutical formulations, and methods of use.